Figure 3.
Associations of patient age, sex, COVID-19 severity, and stage with the diversity of B and T cell repertoires in PBMCs
(A) Heatmap for q values of ANOVA. Sample type, fresh or frozen; sample time, days after symptom onset.
(B–E) Comparison for T_CD4_c02−AQP3, T_CD4_c08−GZMK−FOShigh, T_CD8_c01−LEF1, and T_CD8_c02−GPR183.
(F) Sex differences for T_CD4_c08−GZMK−FOShigh.
(G–I) Age associations of the TCR diversity of T_CD8_c01−LEF1, T_CD8_c05-ZNF683, and T_CD8_c09-SLC4A10 (Spearman’s correlation).
(J) V gene usage of published SARS-CoV-2 neutralized antibodies and their relationship with those differentially used IGHV genes in our dataset. Gini-index was used to quantify the skewness of the V gene usage of the published SARS-CoV-2 neutralized antibodies. IGHV genes differentially used by moderate or severe COVID-19 patients compared with healthy controls and their intersections are shown with different colors. Venn diagram is used to show their overlaps with those published SARS-CoV-2 antibodies. Adjusted p values < 0.05 are indicated (two-sided unpaired Wilcoxon test).